The 10-Year Extended Follow-up of the DACAB Trial (NCT07480629) | Clinical Trial Compass
By InvitationNot Applicable
The 10-Year Extended Follow-up of the DACAB Trial
China500 participantsStarted 2026-03-15
Plain-language summary
The goal of this observational study is to learn about the very long-term effects of different antiplatelet strategies in patients who underwent coronary artery bypass grafting (CABG) and participated in the original DACAB trial. The main questions it aims to answer are:
Does one year of treatment with ticagrelor plus aspirin (dual antiplatelet therapy) after CABG reduce the risk of major adverse cardiovascular events (MACE) over 10 years compared with aspirin alone or ticagrelor alone?
What are the long-term safety outcomes, including major bleeding events, among patients who received different antiplatelet strategies?
Researchers will compare the three originally randomized groups (ticagrelor plus aspirin, ticagrelor alone, and aspirin alone) to see if a one-year course of dual antiplatelet therapy provides a sustained clinical benefit over a decade.
Participants will:
Be contacted by telephone by the central study team for a one-time follow-up interview.
Provide information about their current health status, any cardiovascular events (such as heart attack, stroke, or repeat revascularization procedures) that have occurred since the last follow-up.
Report their current use of medications, including antiplatelet and other cardiovascular drugs.
Allow researchers to request relevant medical records to verify any reported clinical events.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Original enrollment and randomization in the DACAB trial
Exclusion Criteria:
Who explicitly refuse to provide informed consent for the 10-year follow-up
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this trial is specifically a 10-year extended follow-up of the original DACAB trial, does my history with CABG surgery or the antiplatelet therapy I received make me a candidate to be invited into this follow-up study?
2The trial is 'enrolling by invitation only' — can you tell me whether I was part of the original DACAB trial and whether I might receive an invitation, or explain who the invitations are going out to?
3Since the main thing being measured is 4-Point Major Adverse Cardiovascular Events over a very long follow-up period, what does participating actually involve for me day-to-day — are there regular visits, tests, or just periodic check-ins?
4Given that this is a long-term observational follow-up rather than a new treatment trial, how would joining this study interact with any changes to my current antiplatelet therapy or other coronary artery disease treatments my care team might be considering?
5Are there any risks to me personally from participating in a decade-long cardiovascular follow-up study, or is the main commitment one of time and ongoing data sharing rather than any new procedures or medications?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
4-Point Major Adverse Cardiovascular Events (4P-MACE)
Timeframe: From randomization to completion of 10-year follow-up